United Therapeutics(US:UTHR)2025-04-30 10:36Financial Performance - Total revenue reached $794 million, a 17% increase compared to Q1 2024[22] - Tyvaso (DPI and nebulized) generated $466 million in revenue, representing a 25% year-over-year growth[22] - Remodulin revenue increased by 8% year-over-year to $138 million[22] - Orenitram revenue grew by 14% year-over-year to $121 million[22] - Unituxin revenue remained stable at $58 million compared to the previous year[22] Pipeline and Development - TETON 1 and 2 studies for Tyvaso in Idiopathic Pulmonary Fibrosis (IPF) have completed enrollment, with TETON 2 data expected in the second half of 2025 and TETON 1 data expected in the first half of 2026[31,33] - The ADVANCE OUTCOMES study for Ralinepag in Pulmonary Arterial Hypertension (PAH) is nearing full enrollment, with data expected in 2026[41] - The EXPAND study for UKidney is progressing, with the first transplant expected in mid-2025[49] Strategic Outlook - The company is positioned for multiple waves of growth, with a focus on its current commercial portfolio, innovation in Tyvaso IPF/PPF and Ralinepag PAH, and revolution through xenotransplantation and organ alternatives[25]